Advaxis Updates Phase I Trial Survival Data: 23% Of Patients Still Surviving After 2+ Years
Advaxis Updates Phase I Trial Survival Data: 23% Of Patients Still Surviving After 2+ Years
Advaxis, Incorporated (OTCBB: ADXS), has updated survival data for its Phase I trial of its live Listeria vaccine ADXS11-001(formerly named Lovaxin-C) in patients with recurrent, metastatic, carcinoma of the cervix. While the Phase I safety trial was not designed to evaluate efficacy or survival as its primary endpoints, Advaxis has continued to follow the survival of the study participants.
What next?
Posting Komentar